Nimotuzumab

Drug Profile

Nimotuzumab

Alternative Names: Anti-EGFR mAb hR3; BIOMAb EGFR; CIMAher; Cimaher; DE-766; h-R3; KI-0501; KI-0502; OSAG101; Taixinsheng; TheraCIM; TheraCIM hR3; Theraloc; VECTHIX

Latest Information Update: 02 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Center of Molecular Immunology; CIMYM
  • Developer Biocon Biopharmaceuticals; Biotech Pharmaceutical; Center of Molecular Immunology; CIMYM; Daiichi Sankyo Inc; Eurofarma; Gilead Sciences; Innogene Kalbiotech; InnoMab; Kuhnil Pharmaceutical Company; Laboratorios Pisa; Oncoscience
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer; Glioma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaplastic astrocytoma; Brain cancer; Glioblastoma; Glioma; Head and neck cancer; Nasopharyngeal cancer; Oesophageal cancer
  • Phase III Cervical cancer; Gastric cancer; Non-small cell lung cancer; Pancreatic cancer
  • Phase II/III Breast cancer
  • Phase II Colorectal cancer
  • Clinical Phase Unknown Polycystic kidney disease
  • No development reported Prostate cancer
  • Discontinued Brain metastases; Squamous cell cancer

Most Recent Events

  • 19 Feb 2018 Kuhnil Pharmaceutical terminates phase III trial in Gastric cancer (Combination therapy, Second-line therapy or greater, Late-stage disease, Recurrent) in South Korea, Taiwan, Japan (IV) (NCT01813253)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Breast-cancer(First-line therapy, Adjuvant therapy) in USA (IV, Infusion)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Oesophageal-cancer(Combination therapy, Late-stage disease) in China (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top